Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
50%
Ph not_applicable
1
17%
Ph phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
N/A1 (16.7%)

Trials by Status

completed233%
active_not_recruiting117%
unknown117%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_2

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05340270
recruitingphase_3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

NCT03907826
recruitingphase_2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

NCT06455410
unknownphase_1

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

NCT04324307
completedphase_2

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

NCT01003964
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05340270Phase 2

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Active Not Recruiting
NCT03907826Phase 3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
NCT06455410Phase 2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT04324307Phase 1

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Unknown
NCT01003964Phase 2

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

Completed
NCT04805476Not Applicable

Prophylactic Use of Noninvasive Ventilation in the Postoperative Period of Bariatric Surgery

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6